Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 981,686,720
  • Shares Outstanding, K 945,384
  • Annual Sales, $ 45,043 M
  • Annual Income, $ 10,590 M
  • EBIT $ 19,815 M
  • EBITDA $ 21,582 M
  • 60-Month Beta 0.35
  • Price/Sales 15.74
  • Price/Cash Flow 72.95
  • Price/Book 41.16

Options Overview Details

View History
  • Implied Volatility 41.95% (+0.85%)
  • Historical Volatility 27.47%
  • IV Percentile 82%
  • IV Rank 42.59%
  • IV High 64.53% on 04/07/25
  • IV Low 25.20% on 02/06/25
  • Expected Move (DTE 3) 27.56 (2.67%)
  • Put/Call Vol Ratio 0.84
  • Today's Volume 5,551
  • Volume Avg (30-Day) 37,153
  • Put/Call OI Ratio 1.01
  • Today's Open Interest 284,995
  • Open Int (30-Day) 373,918
  • Expected Range 1,003.32 to 1,058.44

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 28 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 7.50
  • Number of Estimates 7
  • High Estimate 8.72
  • Low Estimate 7.00
  • Prior Year 5.32
  • Growth Rate Est. (year over year) +40.98%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1,012.57 +2.39%
on 01/15/26
1,133.95 -8.57%
on 01/08/26
-34.64 (-3.23%)
since 12/19/25
3-Month
793.82 +30.61%
on 10/22/25
1,133.95 -8.57%
on 01/08/26
+227.84 (+28.16%)
since 10/20/25
52-Week
623.78 +66.21%
on 08/08/25
1,133.95 -8.57%
on 01/08/26
+311.08 (+42.87%)
since 01/17/25

Most Recent Stories

More News
Lilly's sofetabart mipitecan receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer

INDIANAPOLIS , Jan. 20, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to sofetabart...

LLY : 1,039.19 (+0.08%)
Stocks Boosted by Chip Demand Optimism

The S&P 500 Index ($SPX ) (SPY ) on Thursday closed up +0.26%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.60%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.32%. March E-mini...

MSTR : 161.47 (-7.05%)
BLK : 1,140.95 (-1.91%)
AMAT : 318.42 (-2.63%)
MPC : 176.72 (+0.62%)
SNDK : 441.02 (+6.62%)
ADI : 301.64 (+0.46%)
MLTX : 16.48 (-1.67%)
$IUXX : 25,213.01 (-1.24%)
COIN : 233.38 (-3.22%)
ASML : 1,323.58 (-2.58%)
ZNH26 : 111-185 (-0.15%)
OXY : 42.81 (+0.26%)
Why Eli Lilly (LLY) Stock Is Down Today

Why Eli Lilly (LLY) Stock Is Down Today

LLY : 1,039.19 (+0.08%)
Stocks Supported by Strength in Chip Makers and US Economic News

The S&P 500 Index ($SPX ) (SPY ) today is up +0.49%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.75%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.07%. March E-mini S&P futures (ESH26...

BLK : 1,140.95 (-1.91%)
MSTR : 161.47 (-7.05%)
AMAT : 318.42 (-2.63%)
MPC : 176.72 (+0.62%)
SNDK : 441.02 (+6.62%)
ADI : 301.64 (+0.46%)
MLTX : 16.48 (-1.67%)
$IUXX : 25,213.01 (-1.24%)
ASML : 1,323.58 (-2.58%)
ZNH26 : 111-185 (-0.15%)
OXY : 42.81 (+0.26%)
ESH26 : 6,901.75 (-1.07%)
A Fresh IPO That Long-Term Investors Shouldn’t Ignore

Aktis Oncology, which recently had its IPO, has gained substantial backing from Big Pharma mainstay Eli Lilly. Investors should take note of the biotech firm.

SFD : 23.28 (-0.72%)
CRWV : 97.09 (-4.09%)
AKTS : 19.42 (-1.67%)
LLY : 1,039.19 (+0.08%)
MDLN : 43.92 (-0.45%)
Eli Lilly Stock Rallies as Ventyx Deal Calms Wegovy Concerns

After tanking on Novo's "Wegovy Pill" release, Eli Lilly shares reversed course. See why investors may like its acquisition of Ventyx Biosciences.

VTYX : 13.86 (-0.22%)
NVO : 60.88 (-2.33%)
LLY : 1,039.19 (+0.08%)
Nvidia Stock Could Be Just a Few Weeks Away from a Major Downside Catalyst. How to Play NVDA Here.

DeepSeek is set to launch its latest V4 model in just a few weeks, drawing parallels to its launch in January 2025 of its R1 model that triggered a selloff in NVDA and other AI names.

NVDA : 181.44 (-2.57%)
TMO : 615.67 (-0.49%)
LLY : 1,039.19 (+0.08%)
What to Expect From Eli Lilly’s Q4 2025 Earnings Report

Eli Lilly is gearing up to announce its fiscal 2025 fourth-quarter earnings in the near term, and analysts project its earnings to rise in double-digits.

XLV : 155.27 (-0.30%)
$SPX : 6,862.14 (-1.12%)
LLY : 1,039.19 (+0.08%)
This NVIDIA Partnership Shows How Big AI Can Really Get

NVIDIA is well-positioned to dominate AI markets across industries and verticals for years to come; analysts point to a 40% upside.

NVDA : 181.44 (-2.57%)
ACHR : 8.87 (+0.11%)
CAT : 639.70 (-0.88%)
LLY : 1,039.19 (+0.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure...

See More

Key Turning Points

3rd Resistance Point 1,084.83
2nd Resistance Point 1,067.39
1st Resistance Point 1,052.89
Last Price 1,039.19
1st Support Level 1,020.95
2nd Support Level 1,003.51
3rd Support Level 989.01

See More

52-Week High 1,133.95
Last Price 1,039.19
Fibonacci 61.8% 939.07
Fibonacci 50% 878.86
Fibonacci 38.2% 818.66
52-Week Low 623.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar